S&P 500   3,746.96 (-1.90%)
DOW   30,738.45 (-1.70%)
QQQ   300.69 (-2.74%)
AAPL   118.85 (-2.63%)
MSFT   224.81 (-1.21%)
FB   254.22 (-0.47%)
GOOGL   2,015.09 (+0.18%)
TSLA   604.08 (-7.52%)
AMZN   2,953.86 (-1.70%)
NVDA   485.39 (-5.23%)
BABA   228.92 (-3.11%)
CGC   30.13 (-9.36%)
GE   13.23 (-1.56%)
MU   82.11 (-7.86%)
NIO   38.09 (-8.28%)
AMD   77.00 (-4.77%)
T   28.74 (+0.07%)
F   11.71 (-3.78%)
ACB   9.50 (-9.18%)
DIS   184.57 (-4.00%)
BA   220.03 (-3.73%)
NFLX   508.88 (-2.27%)
PFE   33.92 (-1.37%)
S&P 500   3,746.96 (-1.90%)
DOW   30,738.45 (-1.70%)
QQQ   300.69 (-2.74%)
AAPL   118.85 (-2.63%)
MSFT   224.81 (-1.21%)
FB   254.22 (-0.47%)
GOOGL   2,015.09 (+0.18%)
TSLA   604.08 (-7.52%)
AMZN   2,953.86 (-1.70%)
NVDA   485.39 (-5.23%)
BABA   228.92 (-3.11%)
CGC   30.13 (-9.36%)
GE   13.23 (-1.56%)
MU   82.11 (-7.86%)
NIO   38.09 (-8.28%)
AMD   77.00 (-4.77%)
T   28.74 (+0.07%)
F   11.71 (-3.78%)
ACB   9.50 (-9.18%)
DIS   184.57 (-4.00%)
BA   220.03 (-3.73%)
NFLX   508.88 (-2.27%)
PFE   33.92 (-1.37%)
S&P 500   3,746.96 (-1.90%)
DOW   30,738.45 (-1.70%)
QQQ   300.69 (-2.74%)
AAPL   118.85 (-2.63%)
MSFT   224.81 (-1.21%)
FB   254.22 (-0.47%)
GOOGL   2,015.09 (+0.18%)
TSLA   604.08 (-7.52%)
AMZN   2,953.86 (-1.70%)
NVDA   485.39 (-5.23%)
BABA   228.92 (-3.11%)
CGC   30.13 (-9.36%)
GE   13.23 (-1.56%)
MU   82.11 (-7.86%)
NIO   38.09 (-8.28%)
AMD   77.00 (-4.77%)
T   28.74 (+0.07%)
F   11.71 (-3.78%)
ACB   9.50 (-9.18%)
DIS   184.57 (-4.00%)
BA   220.03 (-3.73%)
NFLX   508.88 (-2.27%)
PFE   33.92 (-1.37%)
S&P 500   3,746.96 (-1.90%)
DOW   30,738.45 (-1.70%)
QQQ   300.69 (-2.74%)
AAPL   118.85 (-2.63%)
MSFT   224.81 (-1.21%)
FB   254.22 (-0.47%)
GOOGL   2,015.09 (+0.18%)
TSLA   604.08 (-7.52%)
AMZN   2,953.86 (-1.70%)
NVDA   485.39 (-5.23%)
BABA   228.92 (-3.11%)
CGC   30.13 (-9.36%)
GE   13.23 (-1.56%)
MU   82.11 (-7.86%)
NIO   38.09 (-8.28%)
AMD   77.00 (-4.77%)
T   28.74 (+0.07%)
F   11.71 (-3.78%)
ACB   9.50 (-9.18%)
DIS   184.57 (-4.00%)
BA   220.03 (-3.73%)
NFLX   508.88 (-2.27%)
PFE   33.92 (-1.37%)
Log in
NASDAQ:ALXN

Alexion Pharmaceuticals Competitors

$147.10
-1.09 (-0.74 %)
(As of 03/4/2021 01:54 PM ET)
Add
Compare
Today's Range
$147.07
Now: $147.10
$150.12
50-Day Range
$150.37
MA: $155.89
$161.75
52-Week Range
$72.67
Now: $147.10
$162.60
Volume184,566 shs
Average Volume2.84 million shs
Market Capitalization$32.34 billion
P/E Ratio34.37
Dividend YieldN/A
Beta1.33

Competitors

Alexion Pharmaceuticals (NASDAQ:ALXN) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying ALXN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Alexion Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Earnings & Valuation

This table compares Amgen and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.46$7.84 billion$14.8214.89
Alexion Pharmaceuticals$4.99 billion6.48$2.40 billion$9.7415.10

Amgen has higher revenue and earnings than Alexion Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Amgen and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen0111402.56
Alexion Pharmaceuticals017712.36

Amgen presently has a consensus price target of $256.4091, suggesting a potential upside of 15.19%. Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential upside of 3.55%. Given Amgen's stronger consensus rating and higher probable upside, research analysts clearly believe Amgen is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Amgen and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Alexion Pharmaceuticals16.32%23.16%14.76%

Risk & Volatility

Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Insider & Institutional Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Amgen beats Alexion Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Gilead Sciences and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences1111202.46
Alexion Pharmaceuticals017712.36

Gilead Sciences presently has a consensus target price of $96.0370, suggesting a potential upside of 50.76%. Alexion Pharmaceuticals has a consensus target price of $153.1250, suggesting a potential upside of 3.55%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Gilead Sciences and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Alexion Pharmaceuticals16.32%23.16%14.76%

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Gilead Sciences and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.54$5.39 billion$6.1410.30
Alexion Pharmaceuticals$4.99 billion6.48$2.40 billion$9.7415.10

Gilead Sciences has higher revenue and earnings than Alexion Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Gilead Sciences on 8 of the 15 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Vertex Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042312.89
Alexion Pharmaceuticals017712.36

Vertex Pharmaceuticals presently has a consensus target price of $291.8462, indicating a potential upside of 40.26%. Alexion Pharmaceuticals has a consensus target price of $153.1250, indicating a potential upside of 3.55%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion12.90$1.18 billion$4.2948.14
Alexion Pharmaceuticals$4.99 billion6.48$2.40 billion$9.7415.10

Alexion Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Alexion Pharmaceuticals16.32%23.16%14.76%

Summary

Vertex Pharmaceuticals beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends.

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.03$2.12 billion$21.4720.60
Alexion Pharmaceuticals$4.99 billion6.48$2.40 billion$9.7415.10

Alexion Pharmaceuticals has lower revenue, but higher earnings than Regeneron Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Alexion Pharmaceuticals16.32%23.16%14.76%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Regeneron Pharmaceuticals and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals061512.77
Alexion Pharmaceuticals017712.36

Regeneron Pharmaceuticals currently has a consensus price target of $625.8077, suggesting a potential upside of 40.74%. Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential upside of 3.55%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats Alexion Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Profitability

This table compares Biogen and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Alexion Pharmaceuticals16.32%23.16%14.76%

Volatility and Risk

Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Earnings & Valuation

This table compares Biogen and Alexion Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.79$5.89 billion$33.577.83
Alexion Pharmaceuticals$4.99 billion6.48$2.40 billion$9.7415.10

Biogen has higher revenue and earnings than Alexion Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Biogen and Alexion Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5151202.22
Alexion Pharmaceuticals017712.36

Biogen presently has a consensus target price of $304.4667, indicating a potential upside of 15.36%. Alexion Pharmaceuticals has a consensus target price of $153.1250, indicating a potential upside of 3.55%. Given Biogen's higher probable upside, equities analysts clearly believe Biogen is more favorable than Alexion Pharmaceuticals.

Insider and Institutional Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Biogen beats Alexion Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Seagen and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen151112.67
Alexion Pharmaceuticals017712.36

Seagen currently has a consensus target price of $188.4615, suggesting a potential upside of 29.61%. Alexion Pharmaceuticals has a consensus target price of $153.1250, suggesting a potential upside of 3.55%. Given Seagen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Seagen is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Seagen and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.34%20.46%16.67%
Alexion Pharmaceuticals16.32%23.16%14.76%

Institutional & Insider Ownership

87.2% of Seagen shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 31.1% of Seagen shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Seagen has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares Seagen and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million28.56$-158,650,000.00($1.33)-108.67
Alexion Pharmaceuticals$4.99 billion6.48$2.40 billion$9.7415.10

Alexion Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.


Alexion Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$220.70-1.5%$129.34 billion$23.36 billion17.80Dividend Announcement
Analyst Report
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$63.27-0.8%$78.85 billion$22.45 billion65.23Analyst Downgrade
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$206.52-0.9%$54.19 billion$4.16 billion26.08Analyst Upgrade
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$442.38-1.0%$47.86 billion$7.86 billion16.17Analyst Report
Biogen logo
BIIB
Biogen
1.9$262.87-1.4%$40.61 billion$14.38 billion8.70
Seagen logo
SGEN
Seagen
1.7$144.53-2.4%$26.80 billion$916.71 million56.90Decrease in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$119.05-6.3%$21.40 billion$876.29 million-53.87Analyst Upgrade
Insider Selling
News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$139.45-3.5%$16.89 billion$219.75 million-17.81Analyst Report
Incyte logo
INCY
Incyte
1.9$77.96-2.5%$16.71 billion$2.16 billion-49.66
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$75.58-0.7%$13.84 billion$1.70 billion17.30Earnings Announcement
Analyst Report
Analyst Revision
Novavax logo
NVAX
Novavax
1.4$151.48-21.2%$11.69 billion$18.66 million-29.02Earnings Announcement
Insider Selling
Analyst Revision
Gap Up
Repligen logo
RGEN
Repligen
1.5$183.12-9.1%$10.95 billion$270.24 million223.32Analyst Report
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$91.86-3.4%$8.93 billion$788.10 million98.78Unusual Options Activity
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$51.08-3.4%$7.44 billion$1.12 billion106.42Analyst Upgrade
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.9$160.00-2.0%$7.27 billion$1.45 billion15.14Analyst Report
Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$21.19-0.7%$6.65 billion$967.78 million44.15Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$39.84-5.2%$5.67 billion$195.99 million249.00Insider Selling
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$89.81-5.5%$5.05 billion$1.11 billion28.88Analyst Upgrade
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$71.53-2.4%$4.42 billion$806.43 million-10.13Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$57.26-8.9%$4.32 billion$36.13 million-85.46Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
News Coverage
Gap Up
Alkermes logo
ALKS
Alkermes
1.2$18.29-1.9%$2.97 billion$1.17 billion-39.76Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$4.14-4.3%$2.89 billion$901.90 million-23.00
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.08-5.8%$2.78 billion$182.24 million-8.77Earnings Announcement
Analyst Report
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$141.25-4.6%$2.46 billion$120.28 million-142.68Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.14-2.2%$2.16 billion$638.60 million-10.82Analyst Report
Decrease in Short Interest
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.93-8.6%$2.10 billion$48.83 million-14.38Analyst Report
Analyst Revision
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$111.18-0.8%$1.80 billionN/A-10.04Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.27-5.1%$1.69 billion$82.27 million-20.17
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.08-1.1%$1.60 billion$428.41 million14.61Insider Buying
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.11-0.8%$1.60 billion$102.43 million-18.52Analyst Downgrade
Analyst Revision
News Coverage
Codexis logo
CDXS
Codexis
1.5$19.50-7.0%$1.24 billion$68.46 million-55.71Earnings Announcement
Analyst Report
Innoviva logo
INVA
Innoviva
1.4$11.00-0.6%$1.12 billion$261.02 million5.61
BOLT
Bolt Biotherapeutics
1.6$27.08-18.8%$1.11 billionN/A0.00Analyst Report
Analyst Revision
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$24.44-8.5%$1.05 billion$3.57 million-10.96Analyst Report
Gap Up
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$4.32-8.3%$1.00 billion$150,000.00-6.17Earnings Announcement
Analyst Downgrade
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$17.64-1.4%$981.58 million$227.19 million49.00Insider Selling
Gap Up
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.18-3.8%$961.54 million$35.22 million-5.97Earnings Announcement
Gap Up
MannKind logo
MNKD
MannKind
1.4$3.38-7.1%$894.71 million$63.04 million-16.09Analyst Upgrade
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$6.49-10.6%$870.10 million$322.07 million-6.18Upcoming Earnings
Gap Up
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$19.58-6.0%$685.08 million$252 million-2.00Earnings Announcement
Analyst Report
Analyst Revision
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.56-7.6%$647.20 million$59.29 million-23.73Earnings Announcement
Analyst Revision
News Coverage
Agenus logo
AGEN
Agenus
1.6$3.12-8.7%$645.56 million$150.05 million-2.86
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.62-1.2%$580.14 million$143.01 million-1.07
Curis logo
CRIS
Curis
1.3$8.86-9.6%$571.11 million$10 million-10.80Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.21-6.3%$542.11 million$22.27 million-5.00Upcoming Earnings
Geron logo
GERN
Geron
1.4$1.71-0.6%$527.80 million$460,000.00-4.89Upcoming Earnings
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.13-4.8%$478.62 million$109.33 million-2.30Gap Up
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$4.08-12.7%$431.03 million$36.63 million-4.80Analyst Upgrade
News Coverage
XOMA logo
XOMA
XOMA
1.8$35.02-3.2%$398.45 million$18.37 million-31.55Upcoming Earnings
Decrease in Short Interest
Verastem logo
VSTM
Verastem
1.8$2.15-6.0%$387.09 million$17.46 million-1.52Upcoming Earnings
Gap Up
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.